Melatonergic drugs in development

References

• LernerABCaseJDTakahashiYLeeTHMoriWIsolation of melatonin, the pineal factor that lightens melanocytesJ Am Chem Soc19588025872587
   Web of Science ®Google Scholar
• ReiterRJPineal melatonin: cell biology of its synthesis and of its physiological interactionsEndocr Rev19911221511801649044
   PubMed Web of Science ®Google Scholar
• CardinaliDPRosnerJMMetabolism of serotonin by the rat retina in vitroJ Neurochem1971189176917705571113
   PubMed Web of Science ®Google Scholar
• TosiniGMenakerMThe clock in the mouse retina: melatonin synthesis and photoreceptor degenerationBrain Res199878922212289573370
   PubMed Web of Science ®Google Scholar
• Carrillo-VicoACalvoJRAbreuPEvidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine and/or paracrine substanceFASEB J200418353753914715696
   PubMed Web of Science ®Google Scholar
• RaikhlinNTKvetnoyIMMelatonin and enterochromaffine cellsActa Histochem19765511924818867
   PubMed Web of Science ®Google Scholar
• BubenikGAGastrointestinal melatonin: localization, function, and clinical relevanceDig Dis Sci200247102336234812395907
   PubMed Web of Science ®Google Scholar
• KleinDCArylalkylamine N-acetyltransferase: “the Timezyme”J Biol Chem200728274233423717164235
   PubMed Web of Science ®Google Scholar
• BersonDMDunnFATakaoMPhototransduction by retinal ganglion cells that set the circadian clockScience200229555571070107311834835
   PubMed Web of Science ®Google Scholar
• SugdenDMelatonin biosynthesis in the mammalian pineal glandExperientia198945109229322572451
   PubMedGoogle Scholar
• PevetPBothorelBSlottenHSaboureauMThe chronobiotic properties of melatoninCell Tissue Res2002309118319112111548
   PubMed Web of Science ®Google Scholar
• SewerynekEMelatonin and the cardiovascular systemNeuro Endocrinol Lett200223 Suppl 1798312019357
   PubMed Web of Science ®Google Scholar
• Carrillo-VicoAReiterRJLardonePJThe modulatory role of melatonin on immune responsivenessCurr Opin Investig Drugs200675423431
   PubMedGoogle Scholar
• BarrenetxeJDelagrangePMartinexzJAPhysiological and metabolic functions of melatoninJ Physiol Biochem2004601617215352385
   PubMed Web of Science ®Google Scholar
• GenoveseT1Di PaolaRMazzonEMuiàCCaputiAPCuzzocreaSMelatonin limits lung injury in bleomycin treated miceJ Pineal Res200538219820815725342
   PubMed Web of Science ®Google Scholar
• PeresMFMelatonin, the pineal gland and their implications for headache disordersChephalalgia2005256403411
   Web of Science ®Google Scholar
• SrinivasanVPandi-PerumalSRSpenceDWPotential use of melatonergic drugs in analgesia: mechanisms of actionBrain Res Bull2010814–536237120005925
   PubMed Web of Science ®Google Scholar
• SrinivasanVPandi-PerumalSRCardinaliDPPoeggelerBHardelandRMelatonin in Alzheimer’s disease and other neurodegenerative disordersBehav Brain Funct200621516674804
   PubMedGoogle Scholar
• MedeirosCACarvalhedo de BruinPFLopesLAMagalhãesMCde Lourdes SeabraMde BruinVMEffect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled studyJ Neurol2007254445946417404779
   PubMed Web of Science ®Google Scholar
• SoficERimpapaZKundurovicZAntioxidant capacity of the neurohormone melatoninJ Neural Transm2005112334935815666035
   PubMed Web of Science ®Google Scholar
• ReiterRJParedesSDManchesterLCTanDXReducing oxidative/nitrosative stress: a newly-discovered genre for melatoninCrit Rev Biochem Mol Biol200944417520019635037
   PubMed Web of Science ®Google Scholar
• GrantSGMelanMALatimerJJWitt-EnderbyPAMelatonin and breast cancer: cellular mechanisms, clinical studies and future perspectivesExpert Rev Mol Med200911e519193248
   PubMed Web of Science ®Google Scholar
• DavisVLDoddaBRWitt-EnderbyPAThe prevention and treatment of breast cancer using melatoninWatsonRMelatonin in the Promotion of Health2nd edAbingdon, UKTaylor and Francis2011271286
   Google Scholar
• KaramitriA1RenaultNClementNGuillaumeJLJockersRMinireview: Toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetesMol Endocrinol20132781217123323798576
   PubMedGoogle Scholar
• Witt-EnderbyPAClafshenkelWPKotlarczykMPSethiSMelatonin in bone healthWatsonRMelatonin in the Promotion of Health2nd edAbingdon, UKTaylor and Francis2011261270
   Google Scholar
• MariaSWitt-EnderbyPAMelatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting proceduresJ Pineal Res2014562115125
   PubMed Web of Science ®Google Scholar
• CarocciASinicropiMSCatalanoALauriaGGenchiGMelatonin in Parkinson’s DiseaseRanaQAA Synopsis of Parkinson’s DiseaseIntech2014
   Google Scholar
• ReppertSMWeaverDRGodsonCMelatonin receptors step into the light: Cloning and classification of subtypesTrends Pharmacol Sci19961731001028936344
   PubMed Web of Science ®Google Scholar
• Von GallCStehleJHWeaverDRMammalian melatonin receptors: molecular biology and signal transductionCell Tissue Res2002309115116212111545
   PubMed Web of Science ®Google Scholar
• BlaskDESauerLADauchyRTMelatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapyCurr Top Med Chem20022211313211899096
   PubMedGoogle Scholar
• ReppertSMGodsonCMahleCDWeaverDRSlaugenhauptSAGusellaJFMolecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptorProc Natl Acad Sci U S A19959219873487387568007
   PubMed Web of Science ®Google Scholar
• ReppertSMMelatonin receptors: molecular biology of a new family of G protein-coupled receptorsJ Biol Rhythms19971265285319406026
   PubMed Web of Science ®Google Scholar
• DubocovichMLYunKAl-GhoulWMBenloucifSMasanaMISelective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythmsFASEB J19981212121112209737724
   PubMed Web of Science ®Google Scholar
• LiuCWeaverDRJinXMolecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clockNeuron1997191911029247266
   PubMed Web of Science ®Google Scholar
• HuntAEAl-GhoulWMGilletteMUDubocovichMLActivation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clockAm J Physiol Cell Physiol20012801C110C11811121382
   PubMed Web of Science ®Google Scholar
• DubocovichMLMarkowskaMFunctional MT1 and MT2 melatonin receptors in mammalsEndocrine200527210111016217123
   PubMed Web of Science ®Google Scholar
• ComaiSGobbiBUnveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacologyJ Psych Neurosci2014391621
   Web of Science ®Google Scholar
• DoolenSKrauseDNDubocovichMLDucklesSPMelatonin mediates two distinct responses in vascular smooth muscleEur J Pharmacol1998345167699593596
   PubMed Web of Science ®Google Scholar
• NosjeanOFerroMCogéFIdentification of the melatonin-binding site MT3 as the quinone reductase 2J Biol Chem20002754313113131710913150
   PubMed Web of Science ®Google Scholar
• TanDXChenLDPoeggelerBManchesterLCReiterRJMelatonin: a potent, endogenous hydroxyl radical scavengerEndocr J1993145760
   Google Scholar
• RodriguezCMayoJCSainzRMRegulation of antioxidant enzymes: a significant role for melatoninJ Pineal Res20043611914675124
   PubMed Web of Science ®Google Scholar
• Tomas-ZapicoCCoto-MontesAA proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymesJ Pineal Res20053929910416098085
   PubMed Web of Science ®Google Scholar
• RomeroMPGarcia-PerganedaAGuerreroJMOsunaCMembrane-bound calmodulin in Xenopus laevis oocytes as a novel binding site for melatoninFASEB J19981213140114089761784
   PubMed Web of Science ®Google Scholar
• HottaCTGazariniMLBeraldoFHCalcium-dependent modulation by melatonin of the circadian rhythm in malarial parasitesNat Cell Biol20002746646810878815
   PubMed Web of Science ®Google Scholar
• SrinivasanVAhmadAHMohamedMZakariaRMelatonin effects on Plasmodium life cycle: new avenues for therapeutic approachRecent Pat Endocr Metab Immune Drug Discov20126213914722537380
   PubMedGoogle Scholar
• ZhdanovaIVWurtmanRJReganMMTaylorJAShiJPLeclairOUMelatonin treatment for age-related insomniaJ Clin Endocrinol Metab200186104727473011600532
   PubMed Web of Science ®Google Scholar
• LegerDLaudonMZisapelNNocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapyAm J Med20041162919514715322
   PubMed Web of Science ®Google Scholar
• WilsonSJNuttDJAlfordCBritish Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disordersJ Psychopharmacol201024111577160120813762
   PubMed Web of Science ®Google Scholar
• Pandi-PerumalSRTrakhtISpenceDWSrinivasanVDaganYCardinaliDPThe roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disordersNat Clin Pract Neurol20084843644718628753
   PubMedGoogle Scholar
• SrinivasanVSinghJPandi-PerumalSRBrownGMSpenceDWCardinaliDPJet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogsAdv Ther2010271179681320827520
   PubMed Web of Science ®Google Scholar
• DeMuroRLNafzigerANBlaskDEMenhinickAMBertinoJSJrThe absolute bioavailability of oral melatoninJ Clin Pharmacol200040778178410883420
   PubMed Web of Science ®Google Scholar
• ClaustratBBrunJChazotGThe basic physiology and pathophysiology of melatoninSleep Med Rev200591112415649735
   PubMed Web of Science ®Google Scholar
• ArendtJDoes melatonin improve sleep? Efficacy of melatoninBMJ2006332754055055316513724
   PubMed Web of Science ®Google Scholar
• HardelandRNew approaches in the management of insomnia: weighing the advantages of prolonged release melatonin and synthetic melatoninergic agonistsNeuropsych Dis Treat20095341354
   PubMed Web of Science ®Google Scholar
• MiyamotoMPharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disordersCNS Neurosci Ther2009151325119228178
   PubMed Web of Science ®Google Scholar
• de BodinatCGuardiola-LemaitreBMocaërERenardPMuñozCMillanMJAgomelatine, the first melatonergic antidepressant: discovery characterization and developmentNat Rev Drug Discov20109862864220577266
   PubMed Web of Science ®Google Scholar
• LankfordDATasimelteon for insomniaExpert Opin Invest Drugs2011207987993
   PubMed Web of Science ®Google Scholar
• ZemlanFPMulchaheyJJScharfMBMaylebenDWRosenbergRLankfordAThe efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trialJ Clin Psychiatry200566338439015766306
   PubMed Web of Science ®Google Scholar
• KatoKHiraiKNishiyamaKNeurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonistNeuropharmacology200548530131015695169
   PubMed Web of Science ®Google Scholar
• McGechanAWellingtonKRamelteonCNS Drugs200519121057106516332146
   PubMed Web of Science ®Google Scholar
• MiyamotoMPharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disordersCNS Neurosci Ther2009151325119228178
   PubMed Web of Science ®Google Scholar
• StevensonSBrysonSAmaykeDHibberdMStudy to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjectsClin Pharmacol Ther20047522
   Web of Science ®Google Scholar
• CardinaliDPSrinivasanVBrzezinskiABrownGMMelatonin and its analogs in insomnia and depressionJ Pineal Res201252436537521951153
   PubMed Web of Science ®Google Scholar
• Pandi-PerumalSRSrinivasanVSpenceDWRamelteon: a review of its therapeutic potential in sleep disordersAdv Ther200926661362619568703
   PubMed Web of Science ®Google Scholar
• Pandi-PerumalSRSrinivasanVPoeggelerBHardelandRCardinaliDPDrug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteonNat Clin Pract Neurol20073422122817410109
   PubMedGoogle Scholar
• RichardsonGSZeePCWang-WeigandSRodriguezLPengXCircadian phase-shifting effects of repeated ramelteon administration in healthy adultsJ Clin Sleep Med20084545646118853704
   PubMed Web of Science ®Google Scholar
• BellapartJBootsRPotential use of melatonin in sleep and delirium in the critically illBr J Anaesth2012108457258022419624
   PubMed Web of Science ®Google Scholar
• Al-AamaTBrymerCGutmanisIWoolmore-GoodwinSMEsbaughJDasguptaMMelatonin decreases delirium in elderly patients: a randomized, placebo-controlled trialInt J Geriatr Psych2011267687694
   Web of Science ®Google Scholar
• OhtaTMuraoKMiyakeKTakemotoKMelatonin receptor agonists for treating delirium in elderly patients with acute strokeJ Stroke Cerebrovasc Dis20132271107111023017429
   PubMed Web of Science ®Google Scholar
• MillanMJGobertALejeuneFThe novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathwaysJ Pharmacol Exp Ther2003306395496412750432
   PubMed Web of Science ®Google Scholar
• RacagniGRivaMAMolteniRMode of action of agomelatine: synergy between melatonergic and 5-HT2C receptorsWorld J Biol Psychiatry201112857458721999473
   PubMed Web of Science ®Google Scholar
• Bertaina-AngladeVLa RochelleCDBoyerPAMocaerEAntidepressant-like effects of agomelatine (S 20098) in the learned helplessness modelBehav Pharmacol200617870371317110796
   PubMed Web of Science ®Google Scholar
• MillanMJMulti-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic applicationPharmacol Ther2006110213537016522330
   PubMed Web of Science ®Google Scholar
• BogaardsJJHissinkEMBriggsMPrediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modelingEur J Pharm Sci200012211712411102739
   PubMed Web of Science ®Google Scholar
• DolderCRNelsonMSniderMAgomelatine treatment of major depressive disorderAnn Pharmacother200842121822183119033480
   PubMed Web of Science ®Google Scholar
• PappMLitwaEGrucaPMocaërEAnxiolytic-like activity of agomelatine and melatonin in three animal models of anxietyBehav Pharmacol200617191816377959
   PubMed Web of Science ®Google Scholar
• TabeevaGRSergeevAVGromovaSAPossibilities of preventive treatment of migraine with MT1- and MT2 agonist and 5-HT2c receptor antagonist agomelatine (valdoxan)Zh Nevrol Psikhiatr Im S S Korsakova201111193236 Russian22027667
   PubMedGoogle Scholar
• RajaratnamSMWPolymeropoulosMHFisherDMMelatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trialsLancet2009373966248249119054552
   PubMed Web of Science ®Google Scholar
• HardelandRTasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disordersCurr Opin Investig Drugs2009107691701
   Google Scholar
• Vanda Pharma submits NDA for circadian regulator tasimelteon In totally blind RTT News5312011 Available from: http://archive.today/WzzaS
   Google Scholar
• DhillonSClarkeMTasimelteon: first global approvalDrugs201474450551124610704
   PubMed Web of Science ®Google Scholar
• HardelandRInvestigational melatonin receptor agonistsExp Opin Investig Drugs2010196747764
   PubMed Web of Science ®Google Scholar
• HardelandRPoeggelerBMelatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous systemCent Nerv Syst Agents Med Chem201212318921622640220
   PubMedGoogle Scholar
• RivaraSMorMBediniASpadoniGTarziaGMelatonin receptor agonists: SAR and applications to the treatment of sleep-wake disordersCurr Top Med Chem200881195496818673165
   PubMed Web of Science ®Google Scholar
• MulchaheyJJGoldwaterDRZemlanFPA single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatoninLife Sci200475151843185615302228
   PubMed Web of Science ®Google Scholar
• LandoltHPWehrleRAntagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?Eur J Neurosci20092991795180919473234
   PubMed Web of Science ®Google Scholar
• SumayaICMasanaMIDubocovichMLThe antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptorsJ Pineal Res200539217017716098095
   PubMed Web of Science ®Google Scholar
• LiXMBeauJDelagrangePMocaërELéviFCircadian rhythm entrainment with melatonin, melatonin receptor antagonist S22153 or their combination in mice exposed to constant lightJ Pineal Res200437317618415357662
   PubMed Web of Science ®Google Scholar
• WillisJLThe role of ML-23 and other melatonin analogues in the treatment and management of Parkinson’s diseaseDrug News Perspect200518743744416362083
   PubMedGoogle Scholar
• ZlotosDPJockersRCeconERivaraSWitt-EnderbyPAMT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potentialJ Med Chem20145783161318524228714
   PubMed Web of Science ®Google Scholar
• TsotinisAGourgourinisJEleutheriadesADavidsonKSugdenDDesign and synthesis of new N-OMe fluoro-indole melatoninergicsMed Chem20073656157118045206
   PubMed Web of Science ®Google Scholar
• TsotinisAAfroudakisPADavidsonKPrasharASugdenDDesign, synthesis, and melatoninergic activity of new azido- and isothiocyanato-substituted indolesJ Med Chem200750256436644017988084
   PubMed Web of Science ®Google Scholar
• El KazzouliSGriffon du BellayABerteina-RaboinSDelagrangePCaignardDHGuillaumetGDesign and synthesis of 2-phenylimidazo[1,2-a]pyridines as a novel class of melatonin receptor ligandsEur J Med Chem20114694252425721764185
   PubMed Web of Science ®Google Scholar
• KoikeTHoashiYTakaiT1,6-dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT2-selective agonistsJ Med Chem20115493436344421473625
   PubMed Web of Science ®Google Scholar
• CarocciACatalanoALoveceADesign, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptorsBioorg Med Chem201018176496651120674373
   PubMed Web of Science ®Google Scholar
• LandagarayEEttaoussiMLeclercVNew melatonin (MT1/MT2) ligands: fesign and synthesis of (8,9-dihydro-7H-furo[3,2-f] chromen-1-yl) derivativesBioorg Med Chem201422398699624417958
   PubMed Web of Science ®Google Scholar
• TsotinisAVlachouMPapahatjisDPMapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and N-acyl-5-methoxy-1-methyl-tryptaminesJ Med Chem200649123509351916759094
   PubMed Web of Science ®Google Scholar
• DubocovichMLMasanaMIIacobSSauriDMMelatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptorNaunyn Schmiedebergs Arch Pharmacol199735533653759089668
   PubMed Web of Science ®Google Scholar
• LucariniSBartolucciSBediniASynthesis and configuration determination of all enantiopure stereoisomers of the melatonin receptor ligand 4-phenyl-2-propionamidotetralin using an expedient optical resolution of 4-phenyl-2-tetraloneOrg Biomol Chem201210230531322095411
   PubMed Web of Science ®Google Scholar
• BediniALucariniSSpadoniGToward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl- 2-propionamidotetralin derivativesJ Med Chem201154248362837222047556
   PubMed Web of Science ®Google Scholar
• MésangeauCFraiseMDelagrangePPreparation and pharmacological evaluation of a novel series of 2-(phenylthio) benzo[b] thiophenes as selective MT2 receptor ligandsEur J Med Chem20114651835184021392858
   PubMed Web of Science ®Google Scholar
• MarklCClafshenkelWPAttiaMISethiSWitt-EnderbyPAZlotosDPN-acetyl-5-arylalkoxytryptamine analogs: probing the melatonin receptors for MT(1) -selectivityArch Pharm Chem Life Sci201133410666674
   Web of Science ®Google Scholar
• SpadoniGBediniAOrlandoPBivalent ligand approach on N-{2-[(3-methoxyphenyl) methylamino]ethyl}-acetamide: synthesis, binding affinity and intrinsic activity for MT1 and MT2 melatonin receptorsBioorg Med Chem201119164910491621775151
   PubMed Web of Science ®Google Scholar
• RivaraSPalaDLodolaAMT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amidesChemMedChem20127111954196422927210
   PubMed Web of Science ®Google Scholar
• RawashdehOMarondeEThe hormonal Zeitgeber melatonin: role as a circadian modulator in memory processingFront Mol Neurosci20125273322408602
   PubMed Web of Science ®Google Scholar
• Bertaina-AngladeVDrieu-La-RochelleCMocaërESeguinLMemory facilitating effects of agomelatine in the novel object recognition memory paradigm in the ratPharmacol Biochem Behav201198451151721352847
   PubMed Web of Science ®Google Scholar
• GönençSUysalNAçikgözOKayatekinBMEffects of melatonin on oxidative stress and spatial memory impairment induced by acute ethanol treatment in ratsPhysiol Res200554334134815588163
   PubMed Web of Science ®Google Scholar
• PaulisLSimkoFLaudonMCardiovascular effects of melatonin receptor agonistsExpert Opin Investig Drugs2012211116611678
   PubMed Web of Science ®Google Scholar
• LaudonMUradeYHuangZNeu-P11, a novel melatonin agonist: effects on sleep and EEG power spectra in ratsSleep200831SupplA34A35
   Google Scholar
• SheMDengXGuoZNeu-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed ratsPharmacol Res200959424825319429466
   PubMed Web of Science ®Google Scholar
• TianSWLaudonMAntidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent modelsActa Pharmacol Sin201031777578320581849
   PubMed Web of Science ®Google Scholar
• HePOuyangXZhouSA novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer’ diseaseHorm Behav20136411723651610
   PubMed Web of Science ®Google Scholar
• Bustamante-GarcíaRLira-RochaASEspejo-GonzálezOGómez-MartínezAEPicazoOAnxiolytic-like effects of a new 1-N substituted analog of melatonin in pinealectomized ratsProg Neuropsychopharmacol Biol Psychiatry20145113313924495777
   PubMed Web of Science ®Google Scholar
• MaoLChengQGuardiola-LemaîtreBIn vitro and in vivo antitumor activity of melatonin receptor agonistsJ Pineal Res201049321022120609073
   PubMed Web of Science ®Google Scholar
• Ochoa-SanchezRComaiSLacosteBPromotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligandJ Neurosci20113150184391845222171046
   PubMed Web of Science ®Google Scholar
• Ochoa-SanchezRRainerQComaiSAnxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepamProg Neuropsychopharmacol Biol Psychiatry201239231832522789661
   PubMed Web of Science ®Google Scholar
• Ochoa-SanchezRComaiSSpadoniGBediniATarziaGGobbiGMelatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance statesNeurosci Lett201456115616124406151
   PubMed Web of Science ®Google Scholar
• SchuckDCJordãoAKNakabashiMCunhaACFerreiraVFGarciaCRSSynthetic indole and melatonin derivatives exhibit antimalarial activity on the cell cycle of the human malaria parasite Plasmodium falciparumEur J Med Chem20147837538224699367
   PubMed Web of Science ®Google Scholar
• CarocciACatalanoABrunoCN-(Phenoxyalkyl)amides as MT1 and MT2 ligands: Antioxidant properties and inhibition of Ca2+/CaM-dependent kinase IIBioorg Med Chem201321484785123332368
   PubMed Web of Science ®Google Scholar
• PetersJUPolypharmacology – foe or friend?J Med Chem201356228955897123919353
   PubMed Web of Science ®Google Scholar